These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 32873702)

  • 21. Therapeutic indications for antibody-drug conjugates estimated from HER2 and p53 expressions in endometrial carcinoma.
    Nakajima J; Yano M; Zaitsu S; Kamada K; Yabuno A; Hasegawa K; Kobayashi E; Yasuda M
    Hum Pathol; 2024 Oct; 152():105649. PubMed ID: 39154712
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison of mutational profiles between triple-negative and hormone receptor-positive/human epidermal growth factor receptor 2-negative breast cancers in T2N0-1M0 stage: Implications of TP53 and PIK3CA mutations in Korean early-stage breast cancers.
    Lee S; Kim HY; Jung YJ; Jung CS; Im D; Kim JY; Lee SM; Oh SH
    Curr Probl Cancer; 2022 Apr; 46(2):100843. PubMed ID: 35180531
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Histological grade, p53, HER2 and hormone receptor status of synchronous bilateral breast carcinoma.
    Matsuo K; Fukutomi T; Akashi-Tanaka S; Hasegawa T; Tsuda H
    Breast Cancer; 2002; 9(2):127-33. PubMed ID: 12016392
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison of estrogen receptor, progesterone receptor and HER2 results in concurrent ipsilateral samples with invasive breast carcinoma: a retrospective study of 246 biopsies from 119 patients.
    Singh K; Wang Y; Marketkar S; Kalife ET; Steinhoff MM
    Hum Pathol; 2017 Jul; 65():123-132. PubMed ID: 28457730
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Triple-negative and HER2 positive ductal carcinoma in situ of the breast: characteristics, behavior, and biomarker profile.
    Takahashi S; Thike AA; Koh VCY; Sasano H; Tan PH
    Virchows Arch; 2018 Sep; 473(3):275-283. PubMed ID: 30033510
    [TBL] [Abstract][Full Text] [Related]  

  • 26. EZH2 overexpression in different immunophenotypes of breast carcinoma and association with clinicopathologic features.
    Guo S; Li X; Rohr J; Wang Y; Ma S; Chen P; Wang Z
    Diagn Pathol; 2016 Apr; 11():41. PubMed ID: 27113214
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Histopathologic features of breast cancer in Li-Fraumeni syndrome.
    Kuba MG; Lester SC; Bowman T; Stokes SM; Taneja KL; Garber JE; Dillon DA
    Mod Pathol; 2021 Mar; 34(3):542-548. PubMed ID: 32636452
    [TBL] [Abstract][Full Text] [Related]  

  • 28. p53 protein expression in human breast carcinoma: relationship to expression of epidermal growth factor receptor, c-erbB-2 protein overexpression, and oestrogen receptor.
    Poller DN; Hutchings CE; Galea M; Bell JA; Nicholson RA; Elston CW; Blamey RW; Ellis IO
    Br J Cancer; 1992 Sep; 66(3):583-8. PubMed ID: 1355662
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effectiveness of computer-aided diagnosis (CADx) of breast pathology using immunohistochemistry results of core needle biopsy samples for synaptophysin, oestrogen receptor and CK14/p63 for classification of epithelial proliferative lesions of the breast.
    Maeda I; Kubota M; Ohta J; Shinno K; Tajima S; Ariizumi Y; Doi M; Oana Y; Kanemaki Y; Tsugawa K; Ueno T; Takagi M
    J Clin Pathol; 2017 Dec; 70(12):1057-1062. PubMed ID: 28630050
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The prognostic value of p53 and c-erb B-2 immunostaining is overrated for patients with lymph node negative breast carcinoma: a multivariate analysis of prognostic factors in 613 patients with a follow-up of 14-30 years.
    Reed W; Hannisdal E; Boehler PJ; Gundersen S; Host H; Marthin J
    Cancer; 2000 Feb; 88(4):804-13. PubMed ID: 10679650
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Phenotypic and molecular dissection of metaplastic breast cancer and the prognostic implications.
    McCart Reed AE; Kalaw E; Nones K; Bettington M; Lim M; Bennett J; Johnstone K; Kutasovic JR; Saunus JM; Kazakoff S; Xu Q; Wood S; Holmes O; Leonard C; Reid LE; Black D; Niland C; Ferguson K; Gresshoff I; Raghavendra A; Harvey K; Cooper C; Liu C; Kalinowski L; Reid AS; Davidson M; Pearson JV; Pathmanathan N; Tse G; Papadimos D; Pathmanathan R; Harris G; Yamaguchi R; Tan PH; Fox SB; O'Toole SA; Simpson PT; Waddell N; Lakhani SR
    J Pathol; 2019 Feb; 247(2):214-227. PubMed ID: 30350370
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A study on immunohistochemical expression of HER2/Neu and p63 and its association with grade and invasiveness in case of bladder carcinoma.
    Sinha S; Choudhury S; Mishra J; Kundu G; Bera MK; Mondol PP
    Urologia; 2024 May; 91(2):284-288. PubMed ID: 38390685
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical, histopathologic, and immunohistochemical features of microglandular adenosis and transition into in situ and invasive carcinoma.
    Khalifeh IM; Albarracin C; Diaz LK; Symmans FW; Edgerton ME; Hwang RF; Sneige N
    Am J Surg Pathol; 2008 Apr; 32(4):544-52. PubMed ID: 18300793
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Basal-like immunophenotype markers and prognosis in early breast cancer.
    Cassol L; Silveira Graudenz M; Zelmanowicz A; Cancela A; Werutsky G; Rovere RK; Garicochea B
    Tumori; 2010; 96(6):966-70. PubMed ID: 21388060
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cutaneous squamous and neuroendocrine carcinoma: genetically and immunohistochemically different from Merkel cell carcinoma.
    Pulitzer MP; Brannon AR; Berger MF; Louis P; Scott SN; Jungbluth AA; Coit DG; Brownell I; Busam KJ
    Mod Pathol; 2015 Aug; 28(8):1023-32. PubMed ID: 26022453
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Expression of SATB1 and HER2 in breast cancer and the correlations with clinicopathologic characteristics.
    Liu X; Zheng Y; Qiao C; Qv F; Wang J; Ding B; Sun Y; Wang Y
    Diagn Pathol; 2015 May; 10():50. PubMed ID: 25956130
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prognostic value of phosphorylated HER2 in HER2-positive breast cancer patients treated with adjuvant trastuzumab.
    Kurebayashi J; Kanomata N; Yamashita T; Shimo T; Mizutoh A; Moriya T; Sonoo H
    Breast Cancer; 2015 May; 22(3):292-9. PubMed ID: 23749689
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Expression of P53, P63, and C-erbB-2 in endometrioid adenocarcinoma and their clinicopathological significance].
    Hu WF; Liu MQ; Zhao Q
    Ai Zheng; 2004 Sep; 23(9):1021-5. PubMed ID: 15363194
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A comparison among HER2, TP53, PAI-1, angiogenesis, and proliferation activity as prognostic variables in tumours from 408 patients diagnosed with early breast cancer.
    Offersen BV; Alsner J; Ege Olsen K; Riisbro R; Brünner N; Sørensen FB; Sørensen BS; Schlemmer BO; Overgaard J
    Acta Oncol; 2008; 47(4):618-32. PubMed ID: 18465330
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Expression of p40 and laminin 332 in metaplastic spindle cell carcinoma of the breast compared with other malignant spindle cell tumours.
    D'Alfonso TM; Ross DS; Liu YF; Shin SJ
    J Clin Pathol; 2015 Jul; 68(7):516-21. PubMed ID: 25795733
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.